Dihydroergotamine Mesylate from Canada
Dihydroergotamine mesylate is a hydrogenated derivative of ergotamine from rye ergot, administered via injection for acute migraine treatment. Classified under HTS 2939.69.00.00 as 'other' derivatives of rye ergot alkaloids and their salts. The mesylate salt form qualifies under chapter provisions for salts of organic compounds.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Except as provided in heading 9903.04.61, patented pharmaceutical articles as provided for in subdivisions (c) and (d) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
Import Tips
• Require DEA documentation if controlled; ensure HPLC analysis confirms ergot alkaloid structure
• Label as 'not for manufacture of LSD' to prevent Schedule I classification issues